Combined-modality treatment of locally advanced non-small cell lung cancer: Incorporation of novel chemotherapeutic agents

Chest

Volumn 113, Issue 1 SUPPL., 1998, Pages 53S-60S

  Belani, Chandra P ^a   Ramanathan, Ramesh K ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IRINOTECAN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0031965402     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1996. CA Cancer J Clin 1996; 46:5-27
2. Travis WD, Travis LB, Devesa SS. Lung cancer [published erratum appears in Cancer 1995; 75:2979]. Cancer 1995; 75:191-202
3. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89(suppl):225S-33S
4. Naruke T, Goya T, Tsuchiya R, et al. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988; 96:440-47
5. Mountain CF. Value of the new TNM staging system for lung cancer [published erratum appears in Chest 1990; 97:768]. Chest 1989; 96(suppl):47S-49S
6. Perez CA, Bauer M, Edelstein S, et al. Impact of tumor control on survival in carcinoma of the lung treated with irradiation [published erratum appears in Int J Radiat Oncol Biol Phys 1986; 12:2057]. Int J Radiat Oncol Biol Phys 1986; 12:539-47
7. Perez CA, Stanley K, Grundy G, et al. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung: report by the Radiation Therapy Oncology Group. Cancer 1982; 50:1091-99
8. Johnson DH, Einhorn LH, Bartolucci A, et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med 1990; 113:33-38
9. Cox JD, Azarnia N, Byhardt RW, et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990; 8:1543-55
10. Saunders MI, Dische S, Grosch EJ, et al. Experience with CHART [published erratum appears in Int J Radiat Oncol Biol Phys 1991; 21:1683]. Int J Radiat Oncol Biol Phys 1991; 21:871-78
11. Saunders MI, Dische S, Barrett A, et al. Randomized multicenter trials of CHART vs conventional radiotherapy in head and neck and non-small cell lung cancer: an interim report: CHART Steering Committee. Br J Cancer 1996; 73:1455-62
12. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330:153-58
13. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86:673-80
14. Pass HI, Pogrebniak HW, Steinberg SM, et al. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 1992; 53:992-98
15. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992; 326: 524-30
16. Jeremic B, Shibamoto Y, Acimovie L, et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1995; 13:452-58
17. Sause W, Scott C, Taylor S, et al. RTOG 8808 ECOG 4588, preliminary analysis of a phase III trial in regionally advanced unresectable non-small cell lung cancer [abstract A1072]. Proc Am Soc Clin Oncol 1994; 13:325
18. Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 1996; 14:1065-70
19. Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am 1987: 67:1037-49
20. Goldie JH, Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin Oncol 1987; 14:1-7
21. Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993;55:1365-78 (discussion 1373)
22. Skarin A, Jochelson M, Sheldon T, et al. Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol 1989; 40:266-74
23. Martini N, Kris MG, Gralla RJ, et al. The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node metastases (N2 M0). Ann Thorac Surg 1988; 45:370-79
24. Weiden PL, Piantadosi S. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small-cell lung cancer: a phase II study of the Lung Cancer Study Croup. J Natl Cancer Inst 1991; 83:266-73
25. Fossella FV, Ryan B, Dhingra H, et al. Interim report of a prospective randomized trial of neoadjuvant chemotherapy plus surgery vs surgery alone for IIIa non-small cell lung cancer [abstract A817]. Proc Am Soc Clin Oncol 1991; 10:240
26. Darwish S, Minotti V, Crino L, et al. Neoadjuvant cisplatin and etoposide for stage IIIA (clinical N2) non-small cell lung cancer. Am J Clin Oncol 1994; 17:64-67
27. Palazzi M, Cataldo I, Gramaglia A, et al. Preoperative concomitant cisplatin/VP16 and radiotherapy in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1993; 27:621-25
28. Harada M, Dosaka-Akita H, Miyamoto H, et al. Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer 1992; 69:72-77
29. Sugio K, Ishida T, Yokoyama H, et al. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 1992; 52:2903-06
30. Ramanathan RK, Belani CP. Chemotherapy for advanced non-small cell lung cancer: past, present, and future. Semin Oncol 1997; 24:1-15
31. Morton RF, Jett JR, MeGinnis WL, et al. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer: a randomized, phase III trial. Ann Intern Med 1991; 115:681-86
32. Le Chevalier T, Arriagada R, Tarayre M, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-eell lung carcinoma [letter]. J Natl Cancer Inst 1992; 84:58
33. Dillman RO, Seagren SL, Herndon J, et al. Randomized trial of induction chemotherapy plus radiation therapy vs RT alone in stage III non-small cell lung cancer (NSCLC): five-year follow-up of CALGB 84-33 [abstract A1092]. Proc Am Soc Clin Oncol 1993: 12:329
34. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990; 323:940-45
35. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87:198-205
36. Kubota K, Furuse K, Kawahara M, et al. Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer. J Clin Oncol 1994; 12:1547-52
37. Mattson K, Holsti LR, Holsti P, et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 1938; 24:477-82
38. Chan PY, Byfield JE, Kagan AR, et al. Unresectable squamous cell carcinoma of the lung and its management by combined bleomycin and radiotherapy: a clinical study of the enhanced results. Cancer 1976; 37:2671-76
39. Landgren RC, Hussey DH, Barkley HT Jr, et al. Split-course irradiation compared to split-course irradiation plus hydroxyurea in inoperable bronchogenic carcinoma - a randomized study of 53 patients. Cancer 1974; 34:1598-1601
40. Perez CA, Bauer M, Emami BN, et al. Thoracic irradiation with or without levamisole (NSC: 177023) in unresectable non-small cell carcinoma of the lung: a phase III randomized trial of the RTOG. Int J Radiat Oncol Biol Phys 1988; 15:1337-46
41. Douple EB, Eaton WL Jr, Tulloh ME. Skin radiosensitization studies using combined cis-dichlorodiaminneplatinum (II) and radiation. Int J Radiat Oncol Biol Phys 1979; 5:1383-85
42. Douple EB, Richmond RC. Enhancement of the potentiation of radiotherapy by platinum drugs in a mouse tumor. Int J Radiat Oncol Biol Phys 1982; 8:501-03
43. Pinedo HM, Karim AB, van Vliet WH, et al. Daily cisdichlorodiammineplatinum (II) as a radio-enhancer: a preliminary toxicity report. J Cancer Res Clin Oncol 1983; 105:79-82
44. van Harskamp G, Boven E, Vermorken JB, et al. Phase II trial of combined radiotherapy and daily low-dose cisplatin for inoperable, locally advanced non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1987; 13:1735-38
45. Schaake-Koning C, Bartelink H, Adema BH, et al. Radiotherapy and cis-diammine dichloroplatinum (II) as a combined treatment modality for inoperable non-small cell lung cancer: a dose finding study. Int J Radiat Oncol Biol Phys 1986; 12:379-83
46. Soresi E, Clerici M, Grilli R, et al. A randomized clinical trial comparing radiation therapy v radiation therapy plus cis-dichlorodiammine platinum (II) in the treatment of locally advanced non-small cell lung cancer. Semin Oncol 1988; 15:20-25
47. Ansari R, Tokars R, Fisher W, et al. A phase III study of thoracic irradiation with or without concomitant cisplatin in locoregional unresectable non-small cell lung cancer (NSCLC): a Hoosier Oncology Group (HOG) protocol [abstract A823]. Proc Am Soc Clin Oncol 1991; 10:241
48. Trovo MG, Minatel E, Franchin G, et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992; 24:11-15
49. Belani CP, Slawson R, Hiponia D, et al. Concurrent carboplatin (CBDCA) and radiotherapy (RT) for unresectable locally advanced non-small cell lung cancer (NSCLC) [abstract A1196]. Proc Am Soc Clin Oncol 1993; 12:355
50. van der Vijgh WJ. Clinical pharmacokinetics of carboplatin. Clin Pharmacokin 1991; 21:242-61
51. Canetta R, Franks C, Smaldone L, et al. Clinical status of carboplatin. Oncology 1987; 1:61-69
52. Kirsten A, Farrell N, De Careciro GT, et al. New platinum complexes as radiosensitizers [abstract 260]: platinum coordination complexes in cancer chemotherapy. New York: Plenum, 1984; IV-12
53. Belani CP, Egorin MJ, Abrams JS, et al. A novel phannacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide. J Clin Oncol 1989; 7:1896-1902
54. Eisenberger M, Van Echo D, Aisner J. Carboplatin: the experience in head and neck cancer. Semin Oncol 1989; 16:34-41
55. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004-14
56. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994; 5(suppl 6):S3-S6
57. Kumar N. Taxol-induced polymerization of purified tubulin: mechanism of action. J Biol Chem 1981; 256:10435-41
58. Obasaju CK, Johnson SW, Rogatko A, et al. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin Cancer Res 1996; 2:549-52
59. Rowinsky EK, Citardi MJ, Noe DA, et al. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents Taxol and vincristine. J Cancer Res Clin Oncol 1993; 119:727-33
60. Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991; 9:1692-1703
61. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 85:384-88
62. Chang AY, Kim K, Click J, et al. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85:388-94
63. Muggia FM, Vafai D, Natale R, et al. Paclitaxel 3-hour infusion given alone and combined with carboplatin: preliminary results of dose-escalation trials. Semin Oncol 1995; 22:63-66
64. Belani CP, Aisner J, Hiponia D, et: al. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer. Semin Oncol 1995; 22:7-12
65. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995; 13:1860-70
66. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small cell lung cancer: a phase II trial. J Clin Oncol 1996; 14:2054-60
67. Bonomi PD, Kim K, Chang A, et al. Phase III trial comparing etoposide (E) cisplatin (P) versus Taxol (T) with eisplatin-GCSF (G) versus cisplatin in advanced non-small cell lung cancer: Eastern Cooperative Oncology Group (ECOG) [abstract A1145]. Proc Am Soc Clin Oncol 1996; 15:382
68. Tishler RB, Geard CR, Hall EJ, et al. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992; 52:3495-97
69. Choy H, Browne MJ. Paclitaxel as a radiation sensitizer in non-small cell lung cancer. Semin Oncol 1995; 22:70-74
70. Choy H, Akerley W, Safran H, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 1994; 12: 2682-86
71. Kawasaki M, Nakanisi Y, Kuwano K, et al. The utility of p53 immunostaining for the transbronchial biopsy specimens of lung cancer: p53 overexpression may predict poor prognosis and chemoresistance in advanced non-small cell lung cancer [abstract A40], Proc Am Soc Clin Oncol 1996; 5:94
72. Safran H, King T, Choy H, et al. p53 mutations do not predict response to paclitaxel/radiation for non-small cell lung carcinoma. Cancer 1996; 78:1203-10
73. Belani CP, Aisner J, Hiponia D, et al. Paclitaxel and carboplatin with concurrent thoracic radiotherapy for regionally advanced non-small cell lung cancer (NSCLC) [abstract A1201]. Proc Am Soc Clin Oncol 1996; 15:396